AXQ Capital LP Trims Position in Insulet Corporation $PODD

Key Points

• AXQ Capital LP cut its Insulet position by 74.8% in the second quarter, selling 14,968 shares and retaining 5,034 shares valued at approximately $766,000.
• Insulet reported stronger-than-expected quarterly results, with EPS of $1.66 versus the $1.47 consensus estimate and revenue of $801.7 million, up 23.5% year over year.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and an average price target of $195.40, while shares recently opened at $147.48 after trading between $126.40 and $354.88 over the past year.

AXQ Capital LP lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 74.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,034 shares of the medical instruments supplier's stock after selling 14,968 shares during the period. AXQ Capital LP's holdings in Insulet were worth $766,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PODD. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in shares of Insulet in the 4th quarter valued at about $28,000. DV Equities LLC purchased a new stake in shares of Insulet in the fourth quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new position in shares of Insulet during the 4th quarter valued at approximately $29,000.

Insulet Stock Performance

Shares of Insulet stock opened at $147.48 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The stock's 50 day simple moving average is $154.45 and its 200-day simple moving average is $177.27. The stock has a market cap of $10.23 billion, a P/E ratio of 27.57, a P/E/G ratio of 1.16 and a beta of 1.08. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business's revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts predict that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PODD. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $152.00 price target (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. The Goldman Sachs Group reiterated a "buy" rating and set a $205.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Raymond James Financial reissued an "outperform" rating and set a $180.00 target price on shares of Insulet in a report on Thursday, August 6th. Oppenheimer lowered Insulet from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada dropped their price target on Insulet from $245.00 to $160.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source